Payment overview · 2025
General Payments
$1,427.58
60 reported records · 23 companies
Healthcare provider profile · identity verified
Arturo Hernandez, M.D.
Allopathic & Osteopathic Physicians|Family Medicine · EL PASO, TX · NPI 1114112141
Verified facts
What the public records show
CMS Open Payments records show Arturo Hernandez, M.D. received $1,427.58 in general payments during 2025 across 60 reported records.
Globus Medical, Inc. accounted for 28.7% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 29 associated products.
A separate comparison found the same explicitly named product in public Medicare Part D data: Eliquis, Farxiga, Kerendia, Linzess, Mounjaro, Ozempic, Trelegy Ellipta, Zenpep.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported LINZESS as an associated drug or biological on 87954 records involving 21815 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Linzess by this doctor in 2024.
ABBVIE INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYNTHROID as an associated drug or biological on 10655 records involving 4881 distinct recipient NPIs. Public Medicare Part D data also shows 20 claims for Synthroid by this doctor in 2024.
Aimmune Therapeutics, Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ZENPEP as an associated drug or biological on 32144 records involving 12432 distinct recipient NPIs. Public Medicare Part D data also shows 22 claims for Zenpep by this doctor in 2024.
Amgen Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PROLIA as an associated drug or biological on 20867 records involving 11744 distinct recipient NPIs. Public Medicare Part D data also shows 52 claims for Prolia by this doctor in 2024.
Astellas Pharma US Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Myrbetriq as an associated drug or biological on 16 records involving 16 distinct recipient NPIs. Public Medicare Part D data also shows 89 claims for Myrbetriq by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported BRILINTA as an associated drug or biological on 993 records involving 512 distinct recipient NPIs. Public Medicare Part D data also shows 16 claims for Brilinta by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported FARXIGA as an associated drug or biological on 106133 records involving 42906 distinct recipient NPIs. Public Medicare Part D data also shows 68 claims for Farxiga by this doctor in 2024.
AstraZeneca Pharmaceuticals LP reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported SYMBICORT as an associated drug or biological on 71 records involving 51 distinct recipient NPIs. Public Medicare Part D data also shows 32 claims for Symbicort by this doctor in 2024.
Bayer Healthcare Pharmaceuticals Inc. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Kerendia as an associated drug or biological on 138674 records involving 48458 distinct recipient NPIs. Public Medicare Part D data also shows 11 claims for Kerendia by this doctor in 2024.
GlaxoSmithKline, LLC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRELEGY ELLIPTA as an associated drug or biological on 131532 records involving 37148 distinct recipient NPIs. Public Medicare Part D data also shows 92 claims for Trelegy Ellipta by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported JARDIANCE as an associated drug or biological on 47708 records involving 23833 distinct recipient NPIs. Public Medicare Part D data also shows 114 claims for Jardiance by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported MOUNJARO as an associated drug or biological on 186719 records involving 66436 distinct recipient NPIs. Public Medicare Part D data also shows 100 claims for Mounjaro by this doctor in 2024.
Lilly USA, LLC reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported TRULICITY as an associated drug or biological on 71 records involving 57 distinct recipient NPIs. Public Medicare Part D data also shows 215 claims for Trulicity by this doctor in 2024.
Novo Nordisk Inc reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported Ozempic as an associated drug or biological on 261625 records involving 77793 distinct recipient NPIs. Public Medicare Part D data also shows 343 claims for Ozempic by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported ELIQUIS as an associated drug or biological on 87112 records involving 36032 distinct recipient NPIs. Public Medicare Part D data also shows 106 claims for Eliquis by this doctor in 2024.
PFIZER INC. reported payments to this doctor in 2025. Across the 2025 Open Payments General Payment records loaded for this analysis, that same reporting entity reported PAXLOVID as an associated drug or biological on 24465 records involving 15715 distinct recipient NPIs. Public Medicare Part D data also shows 55 claims for Paxlovid by this doctor in 2024.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Globus Medical, Inc. | Unresolved — no canonical attribution shown | $410.22 | 28.7% | 4 | 2025 |
| Bayer Healthcare Pharmaceuticals Inc. | Unresolved — no canonical attribution shown | $176.91 | 12.4% | 16 | 2025 |
| Ardelyx, Inc. | Unresolved — no canonical attribution shown | $123.76 | 8.7% | 5 | 2025 |
| Dexcom, Inc. | Unresolved — no canonical attribution shown | $97.91 | 6.9% | 2 | 2025 |
| Aimmune Therapeutics, Inc. | Unresolved — no canonical attribution shown | $82.92 | 5.8% | 5 | 2025 |
| Lilly USA, LLC | Unresolved — no canonical attribution shown | $77.32 | 5.4% | 4 | 2025 |
| Exact Sciences Corporation | Unresolved — no canonical attribution shown | $54.64 | 3.8% | 3 | 2025 |
| Abbott Laboratories | Unresolved — no canonical attribution shown | $39.10 | 2.7% | 2 | 2025 |
| ABBVIE INC. | Unresolved — no canonical attribution shown | $37.92 | 2.7% | 2 | 2025 |
| Sumitomo Pharma America, Inc. | Unresolved — no canonical attribution shown | $35.14 | 2.5% | 2 | 2025 |
| Amgen Inc. | Unresolved — no canonical attribution shown | $30.97 | 2.2% | 2 | 2025 |
| AstraZeneca Pharmaceuticals LP | Unresolved — no canonical attribution shown | $29.48 | 2.1% | 2 | 2025 |
| Novartis Pharmaceuticals Corporation | Unresolved — no canonical attribution shown | $27.28 | 1.9% | 1 | 2025 |
| Novo Nordisk Inc | Unresolved — no canonical attribution shown | $27.19 | 1.9% | 1 | 2025 |
| Neurelis, Inc. |
Neurelis, Inc. exact · evidence 2025-02-20 |
$26.56 | 1.9% | 1 | 2025 |
| GlaxoSmithKline, LLC. | Unresolved — no canonical attribution shown | $20.96 | 1.5% | 1 | 2025 |
| Astellas Pharma US Inc | Unresolved — no canonical attribution shown | $20.87 | 1.5% | 1 | 2025 |
| GENZYME CORPORATION | Unresolved — no canonical attribution shown | $20.04 | 1.4% | 1 | 2025 |
| PFIZER INC. | Unresolved — no canonical attribution shown | $19.55 | 1.4% | 1 | 2025 |
| Radius Health, Inc. | Unresolved — no canonical attribution shown | $18.56 | 1.3% | 1 | 2025 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | Unresolved — no canonical attribution shown | $17.48 | 1.2% | 1 | 2025 |
| Cumberland Pharmaceuticals, Inc. | Unresolved — no canonical attribution shown | $17.17 | 1.2% | 1 | 2025 |
| Inspire Medical Systems, Inc. | Unresolved — no canonical attribution shown | $15.63 | 1.1% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $1,427.58 | 60 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| Senza Normalized: senza |
Device | Globus Medical, Inc. | $410.22 | 4 | 2025 |
Source payment records
|
|||||
| Kerendia Normalized: kerendia |
Drug | Bayer Healthcare Pharmaceuticals Inc. | $176.91 | 16 | 2025 |
Source payment records
|
|||||
| IBSRELA Normalized: ibsrela |
Drug | Ardelyx, Inc. | $123.76 | 5 | 2025 |
Source payment records
|
|||||
| Dexcom G6 Transmitter Normalized: dexcom g6 transmitter |
Medical Supply | Dexcom, Inc. | $97.91 | 2 | 2025 |
Source payment records
|
|||||
| ZENPEP Normalized: zenpep |
Drug | Aimmune Therapeutics, Inc. | $82.92 | 5 | 2025 |
Source payment records
|
|||||
| ZEPBOUND Normalized: zepbound |
Drug | Lilly USA, LLC | $77.32 | 4 | 2025 |
Source payment records
|
|||||
| The Cologuard Plus Collection Kit Normalized: the cologuard plus collection kit |
Device | Exact Sciences Corporation | $54.64 | 3 | 2025 |
Source payment records
|
|||||
| MOUNJARO Normalized: mounjaro |
Drug | Lilly USA, LLC | $48.88 | 3 | 2025 |
Source payment records
|
|||||
| FREESTYLE LIBRE 3 Normalized: freestyle libre 3 |
Device | Abbott Laboratories | $39.10 | 2 | 2025 |
Source payment records
|
|||||
| GEMTESA Normalized: gemtesa |
Drug | Sumitomo Pharma America, Inc. | $35.14 | 2 | 2025 |
Source payment records
|
|||||
| OTEZLA Normalized: otezla |
Drug | Amgen Inc. | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| REPATHA Normalized: repatha |
Biological | Amgen Inc. | $30.97 | 2 | 2025 |
Source payment records
|
|||||
| LEQVIO Normalized: leqvio |
Drug | Novartis Pharmaceuticals Corporation | $27.28 | 1 | 2025 |
Source payment records
|
|||||
| Ozempic Normalized: ozempic |
Drug | Novo Nordisk Inc | $27.19 | 1 | 2025 |
Source payment records
|
|||||
| VALTOCO Normalized: valtoco |
Drug | Neurelis, Inc. | $26.56 | 1 | 2025 |
Source payment records
|
|||||
| UBRELVY Normalized: ubrelvy |
Drug | ABBVIE INC. | $22.27 | 1 | 2025 |
Source payment records
|
|||||
| TRELEGY ELLIPTA Normalized: trelegy ellipta |
Drug | GlaxoSmithKline, LLC. | $20.96 | 1 | 2025 |
Source payment records
|
|||||
| Veozah Normalized: veozah |
Drug | Astellas Pharma US Inc | $20.87 | 1 | 2025 |
Source payment records
|
|||||
| DUPIXENT Normalized: dupixent |
Biological | GENZYME CORPORATION | $20.04 | 1 | 2025 |
Source payment records
|
|||||
| ELIQUIS Normalized: eliquis |
Drug | PFIZER INC. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| NURTEC ODT Normalized: nurtec odt |
Drug | PFIZER INC. | $19.55 | 1 | 2025 |
Source payment records
|
|||||
| Tymlos Normalized: tymlos |
Drug | Radius Health, Inc. | $18.56 | 1 | 2025 |
Source payment records
|
|||||
| CAPLYTA Normalized: caplyta |
Drug | ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | $17.48 | 1 | 2025 |
Source payment records
|
|||||
| KRISTALOSE Normalized: kristalose |
Drug | Cumberland Pharmaceuticals, Inc. | $17.17 | 1 | 2025 |
Source payment records
|
|||||
| LINZESS Normalized: linzess |
Drug | ABBVIE INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| VIBERZI Normalized: viberzi |
Drug | ABBVIE INC. | $15.65 | 1 | 2025 |
Source payment records
|
|||||
| INSPIRE Normalized: inspire |
Device | Inspire Medical Systems, Inc. | $15.63 | 1 | 2025 |
Source payment records
|
|||||
| BREZTRI Normalized: breztri |
Drug | AstraZeneca Pharmaceuticals LP | $15.05 | 1 | 2025 |
Source payment records
|
|||||
| FARXIGA Normalized: farxiga |
Drug | AstraZeneca Pharmaceuticals LP | $14.43 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
| Open Payments product | Payment year | Part D brand | Part D year | Claims | Match method | Source |
|---|---|---|---|---|---|---|
| ELIQUIS eliquis |
2025 | Eliquis | 2024 | 106 | exact normalized | Medicare Part D |
| FARXIGA farxiga |
2025 | Farxiga | 2024 | 68 | exact normalized | Medicare Part D |
| Kerendia kerendia |
2025 | Kerendia | 2024 | 11 Beneficiary count suppressed |
exact normalized | Medicare Part D |
| LINZESS linzess |
2025 | Linzess | 2024 | 114 | exact normalized | Medicare Part D |
| MOUNJARO mounjaro |
2025 | Mounjaro | 2024 | 100 | exact normalized | Medicare Part D |
| Ozempic ozempic |
2025 | Ozempic | 2024 | 343 | exact normalized | Medicare Part D |
| TRELEGY ELLIPTA trelegy ellipta |
2025 | Trelegy Ellipta | 2024 | 92 | exact normalized | Medicare Part D |
| ZENPEP zenpep |
2025 | Zenpep | 2024 | 22 | exact normalized | Medicare Part D |
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
| Paying company | Payment year | Drug reported by same entity | Open Payments evidence | Part D | Claims | Beneficiaries |
|---|---|---|---|---|---|---|
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | LINZESS open payments reported associated product |
CMS Open Payments — General Payments 87954 supporting records · 21815 recipient NPIs · example record 1201352608 |
Linzess · 2024 Exact normalized brand match · 1 Part D row |
114 | 43 |
| ABBVIE INC. Exact reporting entity; no affiliate inference |
2025 | SYNTHROID open payments reported associated product |
CMS Open Payments — General Payments 10655 supporting records · 4881 recipient NPIs · example record 1201352636 |
Synthroid · 2024 Exact normalized brand match · 1 Part D row |
20 | suppressed by CMS |
| Aimmune Therapeutics, Inc. Exact reporting entity; no affiliate inference |
2025 | ZENPEP open payments reported associated product |
CMS Open Payments — General Payments 32144 supporting records · 12432 recipient NPIs · example record 1249641927 |
Zenpep · 2024 Exact normalized brand match · 1 Part D row |
22 | 11 |
| Amgen Inc. Exact reporting entity; no affiliate inference |
2025 | PROLIA open payments reported associated product |
CMS Open Payments — General Payments 20867 supporting records · 11744 recipient NPIs · example record 1226874448 |
Prolia · 2024 Exact normalized brand match · 1 Part D row |
52 | 27 |
| Astellas Pharma US Inc Exact reporting entity; no affiliate inference |
2025 | Myrbetriq open payments reported associated product |
CMS Open Payments — General Payments 16 supporting records · 16 recipient NPIs · example record 1238599014 |
Myrbetriq · 2024 Exact normalized brand match · 1 Part D row |
89 | 31 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | BRILINTA open payments reported associated product |
CMS Open Payments — General Payments 993 supporting records · 512 recipient NPIs · example record 1206131430 |
Brilinta · 2024 Exact normalized brand match · 1 Part D row |
16 | suppressed by CMS |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | FARXIGA open payments reported associated product |
CMS Open Payments — General Payments 106133 supporting records · 42906 recipient NPIs · example record 1206131362 |
Farxiga · 2024 Exact normalized brand match · 1 Part D row |
68 | 28 |
| AstraZeneca Pharmaceuticals LP Exact reporting entity; no affiliate inference |
2025 | SYMBICORT open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 51 recipient NPIs · example record 1206132610 |
Symbicort · 2024 Exact normalized brand match · 1 Part D row |
32 | 16 |
| Bayer Healthcare Pharmaceuticals Inc. Exact reporting entity; no affiliate inference |
2025 | Kerendia open payments reported associated product |
CMS Open Payments — General Payments 138674 supporting records · 48458 recipient NPIs · example record 1225434663 |
Kerendia · 2024 Exact normalized brand match · 1 Part D row |
11 | suppressed by CMS |
| GlaxoSmithKline, LLC. Exact reporting entity; no affiliate inference |
2025 | TRELEGY ELLIPTA open payments reported associated product |
CMS Open Payments — General Payments 131532 supporting records · 37148 recipient NPIs · example record 1190332369 |
Trelegy Ellipta · 2024 Exact normalized brand match · 1 Part D row |
92 | 35 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | JARDIANCE open payments reported associated product |
CMS Open Payments — General Payments 47708 supporting records · 23833 recipient NPIs · example record 1186464557 |
Jardiance · 2024 Exact normalized brand match · 1 Part D row |
114 | 36 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | MOUNJARO open payments reported associated product |
CMS Open Payments — General Payments 186719 supporting records · 66436 recipient NPIs · example record 1186464455 |
Mounjaro · 2024 Exact normalized brand match · 1 Part D row |
100 | 23 |
| Lilly USA, LLC Exact reporting entity; no affiliate inference |
2025 | TRULICITY open payments reported associated product |
CMS Open Payments — General Payments 71 supporting records · 57 recipient NPIs · example record 1186464601 |
Trulicity · 2024 Exact normalized brand match · 1 Part D row |
215 | 53 |
| Novo Nordisk Inc Exact reporting entity; no affiliate inference |
2025 | Ozempic open payments reported associated product |
CMS Open Payments — General Payments 261625 supporting records · 77793 recipient NPIs · example record 1188130076 |
Ozempic · 2024 Exact normalized brand match · 1 Part D row |
343 | 89 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | ELIQUIS open payments reported associated product |
CMS Open Payments — General Payments 87112 supporting records · 36032 recipient NPIs · example record 1228794063 |
Eliquis · 2024 Exact normalized brand match · 1 Part D row |
106 | 33 |
| PFIZER INC. Exact reporting entity; no affiliate inference |
2025 | PAXLOVID open payments reported associated product |
CMS Open Payments — General Payments 24465 supporting records · 15715 recipient NPIs · example record 1228794432 |
Paxlovid · 2024 Exact normalized brand match · 1 Part D row |
55 | 54 |
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 1528 | 528 |
| Metformin Hcl | Metformin Hcl | 1060 | 357 |
| Losartan Potassium | Losartan Potassium | 1047 | 358 |
| Lisinopril | Lisinopril | 909 | 301 |
| Levothyroxine Sodium | Levothyroxine Sodium | 875 | 266 |
| Omeprazole | Omeprazole | 751 | 328 |
| Gabapentin | Gabapentin | 709 | 241 |
| Amlodipine Besylate | Amlodipine Besylate | 702 | 244 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 585 | 220 |
| Alendronate Sodium | Alendronate Sodium | 545 | 200 |
| Hydrochlorothiazide | Hydrochlorothiazide | 456 | 176 |
| Tamsulosin Hcl | Tamsulosin Hcl | 443 | 154 |
| Hydroxyzine Hcl | Hydroxyzine Hcl | 402 | 172 |
| Meloxicam | Meloxicam | 365 | 176 |
| Glipizide | Glipizide | 360 | 119 |
| Hydralazine Hcl | Hydralazine Hcl | 359 | 159 |
| Ozempic | Semaglutide | 343 | 89 |
| Tramadol Hcl | Tramadol Hcl | 327 | 99 |
| Simvastatin | Simvastatin | 311 | 101 |
| Metoprolol Succinate | Metoprolol Succinate | 304 | 104 |
| Alprazolam | Alprazolam | 296 | 77 |
| Fluticasone Propionate | Fluticasone Propionate | 264 | 151 |
| Famotidine | Famotidine | 262 | 121 |
| Zolpidem Tartrate | Zolpidem Tartrate | 260 | 47 |
| Prednisone | Prednisone | 247 | 186 |
| Montelukast Sodium | Montelukast Sodium | 245 | 95 |
| Metoprolol Tartrate | Metoprolol Tartrate | 241 | 84 |
| Azithromycin | Azithromycin | 237 | 206 |
| Pantoprazole Sodium | Pantoprazole Sodium | 232 | 83 |
| Ibuprofen | Ibuprofen | 229 | 97 |
| Januvia | Sitagliptin Phosphate | 226 | 73 |
| Trulicity | Dulaglutide | 215 | 53 |
| Carvedilol | Carvedilol | 205 | 71 |
| Furosemide | Furosemide | 201 | 90 |
| Memantine Hcl | Memantine Hcl | 199 | 75 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 187 | 63 |
| Nifedipine Er | Nifedipine | 183 | 72 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 172 | 120 |
| Omega-3 Acid Ethyl Esters | Omega-3 Acid Ethyl Esters | 169 | 78 |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 162 | 55 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 148 | 70 |
| Buspirone Hcl | Buspirone Hcl | 144 | 50 |
| Trazodone Hcl | Trazodone Hcl | 142 | 44 |
| Clopidogrel | Clopidogrel Bisulfate | 137 | 50 |
| Vitamin D2 | Ergocalciferol (Vitamin D2) | 136 | 61 |
| Dicyclomine Hcl | Dicyclomine Hcl | 133 | 81 |
| Pioglitazone Hcl | Pioglitazone Hcl | 132 | 49 |
| Finasteride | Finasteride | 130 | 43 |
| Pregabalin | Pregabalin | 125 | 32 |
| Diclofenac Sodium | Diclofenac Sodium | 124 | 60 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 123 | 71 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 122 | 31 |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 120 | 37 |
| Nitrofurantoin Mono-Macro | Nitrofurantoin Monohyd/M-Cryst | 120 | 99 |
| Paroxetine Hcl | Paroxetine Hcl | 119 | 37 |
| Meclizine Hcl | Meclizine Hcl | 118 | 71 |
| Jardiance | Empagliflozin | 114 | 36 |
| Linzess | Linaclotide | 114 | 43 |
| Ketoconazole | Ketoconazole | 113 | 87 |
| Eliquis | Apixaban | 106 | 33 |
| Pravastatin Sodium | Pravastatin Sodium | 103 | 35 |
| Amoxicillin-Clavulanate Potass | Amoxicillin/Potassium Clav | 101 | 83 |
| Mounjaro | Tirzepatide | 100 | 23 |
| Clonazepam | Clonazepam | 99 | 16 |
| Glipizide Er | Glipizide | 98 | 32 |
| Glimepiride | Glimepiride | 96 | 36 |
| Candesartan Cilexetil | Candesartan Cilexetil | 94 | 25 |
| Tizanidine Hcl | Tizanidine Hcl | 92 | 59 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 92 | 35 |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 91 | 30 |
| Myrbetriq | Mirabegron | 89 | 31 |
| Lidocaine | Lidocaine | 87 | 41 |
| Sucralfate | Sucralfate | 85 | 51 |
| Clindamycin Hcl | Clindamycin Hcl | 83 | 65 |
| Sertraline Hcl | Sertraline Hcl | 83 | 29 |
| Allopurinol | Allopurinol | 82 | 31 |
| Duloxetine Hcl | Duloxetine Hcl | 82 | 21 |
| Fluconazole | Fluconazole | 82 | 51 |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 81 | 44 |
| Cyanocobalamin Injection | Cyanocobalamin (Vitamin B-12) | 75 | 52 |
| Metformin Hcl Er | Metformin Hcl | 75 | 23 |
| Sulfamethoxazole-Trimethoprim | Sulfamethoxazole/Trimethoprim | 75 | 61 |
| Donepezil Hcl | Donepezil Hcl | 73 | 24 |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 72 | 20 |
| Acetaminophen-Codeine | Acetaminophen With Codeine | 70 | 25 |
| Farxiga | Dapagliflozin Propanediol | 68 | 28 |
| Fluoxetine Hcl | Fluoxetine Hcl | 68 | 27 |
| Ezetimibe | Ezetimibe | 66 | 25 |
| Atenolol | Atenolol | 63 | 17 |
| Toujeo Solostar | Insulin Glargine,hum.Rec.Anlog | 62 | 24 |
| Xarelto | Rivaroxaban | 62 | 16 |
| Escitalopram Oxalate | Escitalopram Oxalate | 60 | 20 |
| Paxlovid | Nirmatrelvir/Ritonavir | 55 | 54 |
| Quetiapine Fumarate | Quetiapine Fumarate | 55 | 12 |
| Mirtazapine | Mirtazapine | 54 | 19 |
| Prolia | Denosumab | 52 | 27 |
| Spironolactone | Spironolactone | 52 | 28 |
| Megestrol Acetate | Megestrol Acetate | 51 | 23 |
| Baclofen | Baclofen | 50 | 15 |
| Enalapril Maleate | Enalapril Maleate | 50 | 15 |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 47 | 42 |
| Citalopram Hbr | Citalopram Hydrobromide | 47 | 13 |
| Clonidine Hcl | Clonidine Hcl | 47 | 21 |
| Repatha Syringe | Evolocumab | 47 | suppressed |
| Neomycin-Polymyxin-Hc | Neomycin/Polymyxin B/Hydrocort | 46 | 39 |
| Repatha Sureclick | Evolocumab | 46 | 11 |
| Potassium Chloride | Potassium Chloride | 43 | 18 |
| Propranolol Hcl | Propranolol Hcl | 43 | 17 |
| Naproxen | Naproxen | 42 | 21 |
| Janumet | Sitagliptin Phos/Metformin Hcl | 39 | 12 |
| Hydrocortisone | Hydrocortisone | 38 | 25 |
| Methylprednisolone | Methylprednisolone | 38 | 32 |
| Vascepa | Icosapent Ethyl | 38 | 13 |
| Oxybutynin Chloride | Oxybutynin Chloride | 37 | suppressed |
| Lactulose | Lactulose | 36 | suppressed |
| Levofloxacin | Levofloxacin | 36 | 30 |
| Tresiba Flextouch U-100 | Insulin Degludec | 36 | 13 |
| Bupropion Xl | Bupropion Hcl | 35 | 11 |
| Levetiracetam | Levetiracetam | 35 | suppressed |
| Tobramycin | Tobramycin | 35 | 29 |
| Xifaxan | Rifaximin | 35 | suppressed |
| Celecoxib | Celecoxib | 34 | 15 |
| Telmisartan | Telmisartan | 34 | suppressed |
| Dropsafe Prep Pads | Alcohol Antiseptic Pads | 33 | 13 |
| Symbicort | Budesonide/Formoterol Fumarate | 32 | 16 |
| Terbinafine Hcl | Terbinafine Hcl | 32 | 23 |
| Chlorthalidone | Chlorthalidone | 31 | suppressed |
| Lorazepam | Lorazepam | 30 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 30 | suppressed |
| Clobetasol Propionate | Clobetasol Propionate | 29 | 12 |
| Olmesartan-Hydrochlorothiazide | Olmesartan/Hydrochlorothiazide | 27 | suppressed |
| Valsartan | Valsartan | 27 | suppressed |
| Azelastine Hcl | Azelastine Hcl | 26 | 19 |
| Basaglar Kwikpen U-100 | Insulin Glargine,hum.Rec.Anlog | 26 | suppressed |
| Fenofibrate | Fenofibrate | 26 | suppressed |
| Gemfibrozil | Gemfibrozil | 25 | suppressed |
| Tradjenta | Linagliptin | 25 | suppressed |
| Humalog Kwikpen U-100 | Insulin Lispro | 24 | 12 |
| Ciclopirox | Ciclopirox | 23 | 15 |
| Insulin Lispro Kwikpen U-100 | Insulin Lispro | 23 | 12 |
| Oseltamivir Phosphate | Oseltamivir Phosphate | 23 | 23 |
| Pentoxifylline | Pentoxifylline | 23 | suppressed |
| Promethazine Hcl | Promethazine Hcl | 23 | 19 |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 23 | suppressed |
| Labetalol Hcl | Labetalol Hcl | 22 | suppressed |
| Procto-Med Hc | Hydrocortisone | 22 | 14 |
| Sildenafil Citrate | Sildenafil Citrate | 22 | suppressed |
| Zenpep | Lipase/Protease/Amylase | 22 | 11 |
| Telmisartan-Hydrochlorothiazid | Telmisartan/Hydrochlorothiazid | 21 | suppressed |
| Lantus | Insulin Glargine,hum.Rec.Anlog | 20 | suppressed |
| Synthroid | Levothyroxine Sodium | 20 | suppressed |
| Tresiba Flextouch U-200 | Insulin Degludec | 20 | suppressed |
| Verapamil Er | Verapamil Hcl | 20 | suppressed |
| Benazepril Hcl | Benazepril Hcl | 19 | suppressed |
| Dutasteride | Dutasteride | 19 | suppressed |
| Lovastatin | Lovastatin | 19 | suppressed |
| Hydroxychloroquine Sulfate | Hydroxychloroquine Sulfate | 18 | suppressed |
| Methocarbamol | Methocarbamol | 18 | suppressed |
| Oxycodone Hcl | Oxycodone Hcl | 18 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 18 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 17 | suppressed |
| Glipizide-Metformin | Glipizide/Metformin Hcl | 17 | suppressed |
| Levocetirizine Dihydrochloride | Levocetirizine Dihydrochloride | 17 | suppressed |
| Metronidazole | Metronidazole | 17 | 14 |
| Naloxone Hcl | Naloxone Hcl | 17 | 15 |
| Nitroglycerin | Nitroglycerin | 17 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 17 | suppressed |
| Ursodiol | Ursodiol | 17 | suppressed |
| Amitriptyline Hcl | Amitriptyline Hcl | 16 | suppressed |
| Brilinta | Ticagrelor | 16 | suppressed |
| Desvenlafaxine Succinate Er | Desvenlafaxine Succinate | 16 | suppressed |
| Dexlansoprazole Dr | Dexlansoprazole | 16 | suppressed |
| Icosapent Ethyl | Icosapent Ethyl | 16 | suppressed |
| Janumet Xr | Sitagliptin Phos/Metformin Hcl | 16 | suppressed |
| Eszopiclone | Eszopiclone | 15 | suppressed |
| Liothyronine Sodium | Liothyronine Sodium | 15 | suppressed |
| Synjardy Xr | Empagliflozin/Metformin Hcl | 15 | suppressed |
| Acyclovir | Acyclovir | 14 | 11 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 14 | suppressed |
| Estradiol | Estradiol | 14 | suppressed |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 14 | suppressed |
| Ramipril | Ramipril | 14 | suppressed |
| Alcohol Prep Pads | Alcohol Antiseptic Pads | 13 | suppressed |
| Azelastine-Fluticasone | Azelastine/Fluticasone | 13 | suppressed |
| Breztri Aerosphere | Budesonide/Glycopyr/Formoterol | 13 | suppressed |
| Candesartan-Hydrochlorothiazid | Candesartan/Hydrochlorothiazid | 13 | suppressed |
| Cholestyramine | Cholestyramine (With Sugar) | 13 | suppressed |
| Irbesartan-Hydrochlorothiazide | Irbesartan/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 13 | suppressed |
| Ultra-Fine Mini Pen Needle | Pen Needle, Diabetic | 13 | suppressed |
| Warfarin Sodium | Warfarin Sodium | 13 | suppressed |
| Amlodipine Besylate-Benazepril | Amlodipine Besylate/Benazepril | 12 | suppressed |
| Humalog Kwikpen U-200 | Insulin Lispro | 12 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 12 | suppressed |
| Lamotrigine | Lamotrigine | 12 | suppressed |
| Levemir Flexpen | Insulin Detemir | 12 | suppressed |
| Morphine Sulfate Er | Morphine Sulfate | 12 | suppressed |
| Nabumetone | Nabumetone | 12 | suppressed |
| Olanzapine | Olanzapine | 12 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 12 | suppressed |
| Aimovig Autoinjector | Erenumab-Aooe | 11 | suppressed |
| Alcohol Pads | Alcohol Antiseptic Pads | 11 | suppressed |
| Butalbital-Acetaminophen-Caffe | Butalb/Acetaminophen/Caffeine | 11 | suppressed |
| Fiasp Flextouch | Insulin Aspart (Niacinamide) | 11 | suppressed |
| Kerendia | Finerenone | 11 | suppressed |
| Loperamide | Loperamide Hcl | 11 | suppressed |
| Neomycin-Polymyxin-Hydrocort | Neomycin/Polymyxin B/Hydrocort | 11 | suppressed |
| Novolog Flexpen | Insulin Aspart | 11 | suppressed |
| Phenytoin Sodium Extended | Phenytoin Sodium Extended | 11 | suppressed |
| Scopolamine | Scopolamine | 11 | suppressed |
| Venlafaxine Hcl | Venlafaxine Hcl | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $1,427.58 · 60 records | Globus Medical, Inc. | BREZTRI, CAPLYTA, DUPIXENT, Dexcom G6 Transmitter, ELIQUIS, FARXIGA, FREESTYLE LIBRE 3, GEMTESA, IBSRELA, INSPIRE, KRISTALOSE, Kerendia, LEQVIO, LINZESS, MOUNJARO, NURTEC ODT, OTEZLA, Ozempic, REPATHA, Senza, TRELEGY ELLIPTA, The Cologuard Plus Collection Kit, Tymlos, UBRELVY, VALTOCO, VIBERZI, Veozah, ZENPEP, ZEPBOUND | 16 | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- What role, if any, does Eliquis play in your treatment recommendations for me?
- How do you evaluate evidence when you have a financial relationship with ABBVIE INC.?
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error